Drug Target Review

Engineering the next generation of T-cell engagers

Explore the evolution of T-cell engagers, from experimental concepts to effective therapies for haematologic malignancies.
Mena FN

Leads Biolabs' GPRC5D/CD3 Bispecific T-Cell Engager LBL-034 Earns FDA Fast Track Designation-Accelerating Launch Of Potential Best-In-Class Therapy For Relapsed/Refractory ...

Dr. Charles Cai, Chief Medical Officer of Leads Biolabs, stated: “The sequential regulatory achievements of LBL-034-including Orphan Drug Designations from FDA, followed by FDA Fast Track ...
Cure Today

FDA Fast Tracks IBI3003 For Relapsed/Refractory Myeloma

IBI3003 targets GPRC5D, BCMA, and CD3, showing high response rates in heavily pretreated multiple myeloma patients. Fast track designation facilitates development and review of treatments addressing ...
The New York Times

The Best Dining Tables

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Katherine Burns Olson Katherine Burns Olson is a design editor covering decor ...
National Academies of Sciences%2c Engineering%2c and Medicine

Review of DoD’s Occupational Exposure Limit for TCE

A study will be conducted to review the methods the Department of Defense proposes for determining occupational exposure guidelines for trichloroethylene (TCE) in situations where vapor intrusion is ...